

## Garivulimab

Cat. No.:	HY-P99633
CAS No.:	2342597-81-1
Target:	PD-1/PD-L1; Apoptosis
Pathway:	Immunology/Inflammation; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity <sup>[1]</sup> .
<b>In Vitro</b>	Garivulimab (BGB-A333) specifically targets and binds to PD-L1, blocking interaction to its receptor, PD-1 on T cell, reversing T cell inactivation, and increases T cell expansion resulting in cytotoxic T cell-mediated antitumor immune response against PD-L1-expressing tumor cells. Garivulimab also inhibits PD-L1-induced apoptosis of activated CD8+ T cells and increases T cell proliferation <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA